Research

Latest news

Merck's Keytruda Approved for 40th Indication: First-Line Treatment for Endometrial Cancer

Merck's Keytruda Approved for 40th Indication: First-Line Treatment for Endometrial Cancer

2024-06-20

On June 17, 2024, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) in combination with chemotherapy drugs carboplatin and paclitaxel, followed by pembrolizumab monotherapy, for adult patients with primary advanced or recurrent endometrial carcinoma.

READ MORE

Focusing on the synergistic regulation of the intestine and liver to revitalize liver vitality from the source.

Focusing on the synergistic regulation of the intestine and liver to revitalize liver vitality from the source.

2024-06-06

BIOCENTER LIVERWELL (English name: LIVERWELL) is a systemic liver care dietary supplement under BIOCENTER, a century-old North American life science brand.

READ MORE

Breakthrough in the fight against resistance in metastatic breast cancer

Breakthrough in the fight against resistance in metastatic breast cancer

2023-11-20

A team of researchers at the Medical University of Vienna has discovered that dormant tumor cells surviving chemotherapy can be targeted through the inhibition of a specific protein called P-glycoprotein (P-gp).

READ MORE

World-first research breakthrough sparks new hope for bowel cancer patients

World-first research breakthrough sparks new hope for bowel cancer patients

2023-11-09

Every year, over 15,500 Australians are diagnosed with bowel cancer, and it is the second leading cause of cancer deaths in the country. Over 1,700 (one in ten) of those diagnosed are young Australians aged under 50, and this incidence is increasing.

READ MORE

FDA Approves Ardelyx's Kidney Disease-Related Drug

FDA Approves Ardelyx's Kidney Disease-Related Drug

2023-10-27

The U.S. Food and Drug Administration (FDA) has approved Ardelyx's drug to treat high phosphate levels in patients with chronic kidney disease (CKD), the company said on Tuesday, more than two years after it was initially rejected.

READ MORE

Drug-delivery technique for brain cancer shows growing promise

Drug-delivery technique for brain cancer shows growing promise

2023-10-18

A technique developed by University of Texas at Dallas and UT Southwestern Medical Center researchers to deliver medication through the blood-brain barrier has shown promise in a preclinical study for treating glioblastoma, the most common human brain cancer.

READ MORE

Gut Microbiome Variations May Be Predictive of Precancerous Colonic Lesions, CRC

Gut Microbiome Variations May Be Predictive of Precancerous Colonic Lesions, CRC

2023-10-16

People with precancerous colonic lesions show significant differences in their gut microbiome compared to the general population up to 5 years before the lesions develop, according to a large, 22-year analysis from the Dutch Microbiome Project cohort study.

READ MORE

European Commission Approves Pfizer’s LITFULO™ for Adolescents and Adults With Severe Alopecia Areata

European Commission Approves Pfizer’s LITFULO™ for Adolescents and Adults With Severe Alopecia Areata

2023-09-19

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for LITFULO™ (ritlecitinib) to treat adults and adolescents 12 years of age and older with severe alopecia areata.

READ MORE

< 1 2 > proceed page